EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Feminizing Therapy in People With Klinefelter Syndrome and Gender Incongruence: Considerations for Treatment Without Testosterone Blockers

Maaike Kroon iD, Tamira Klaziene Klooker, Sabine Elisabeth Hannema, Martin Den Heijer

Andrology · 2026-07-02

DOI: 10.1111/andr.70290 ↗

At a glance

Journal article in Andrology, published online on 2026-07-02. Written by Maaike Kroon and 3 co-authors. Institution: Amsterdam UMC location Vrije Universiteit Amsterdam, Center of Expertise on Gender Dysphoria, Amsterdam, The Netherlands. 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Klinefelter syndrome (KS; 47, XXY) usually involves male sex development and gender identity. Small studies suggest gender incongruence may be more common in KS, but feminizing gender‑affirming hormone therapy in this group has been scarcely reported.

Objectives

To evaluate current feminizing hormone therapy in individuals with KS and the number of individuals with KS attending our gender clinic. Materials and Methods We conducted a care evaluation of individuals with KS referred to the Center of Expertise on Gender Dysphoria (Amsterdam UMC) between February 1972 and May 2025, collecting data on KS diagnosis, testosterone use, referral age, feminizing hormone therapy, and hormone concentrations.

Results

Eight (0.12%) people had KS. Median age at KS diagnosis was 25.3 years (IQR 16.9–37.5, n = 8), and at gender clinic intake 45.3 years (IQR 34.2–52.2, n = 8). Among estradiol users, median age was 45.7 years (IQR 42.4–57.1, n = 6). None of those retaining their testes use testosterone blockers (follow‑up: median 5.4 years (3.6–7.7), n = 5).

Discussion

In KS, estradiol alone may sufficiently suppress testosterone. KS prevalence in our cohort does not exceed that of the general population.

Conclusion

Given KS‑related hypogonadism, estradiol monotherapy may be an appropriate first‑line feminizing hormone therapy, avoiding routine use of testosterone blockers.

Subjects

Author keywords

Klinefelter syndromeestradiolgender dysphoriagender‐affirming carehormone replacement therapytransgender persons

Authors and institutions

  • Amsterdam UMC location Vrije Universiteit Amsterdam, Center of Expertise on Gender Dysphoria, Amsterdam, The Netherlands.
  • Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
  • Amsterdam Public Health, Health Behaviors and Chronic Diseases, Amsterdam, The Netherlands.
  • Amsterdam UMC location University of Amsterdam, Paediatric Endocrinology, Amsterdam, The Netherlands.
  • Amsterdam Reproduction and Development, Amsterdam, The Netherlands.

ORCID profiles: Maaike Kroon

Cite

APA

Kroon, M., Klooker, T. K., Hannema, S. E., & Den Heijer, M. (2026). Feminizing Therapy in People With Klinefelter Syndrome and Gender Incongruence: Considerations for Treatment Without Testosterone Blockers. Andrology. https://doi.org/10.1111/andr.70290

Vancouver

Kroon M, Klooker TK, Hannema SE, Den Heijer M. Feminizing Therapy in People With Klinefelter Syndrome and Gender Incongruence: Considerations for Treatment Without Testosterone Blockers. Andrology. 2026. doi:10.1111/andr.70290

BibTeX
@article{Kroon2026,
  author = {Kroon, Maaike and Klooker, Tamira Klaziene and Hannema, Sabine Elisabeth and Den Heijer, Martin},
  title = {Feminizing Therapy in People With Klinefelter Syndrome and Gender Incongruence: Considerations for Treatment Without Testosterone Blockers},
  journal = {Andrology},
  year = {2026},
  doi = {10.1111/andr.70290}
}
Start for free →